Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Inclusion Criteria:

• Have had a diagnosis of Crohn's disease (CD) or perianal fistulizing CD establishedat least 3 months prior to enrollment confirmed by clinical, endoscopic, andhistological criteria.

• Have obesity body mass index 30 kilograms per meter squared (BMI ≥30 kg/m2), oroverweight (BMI ≥27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of theseweight-related comorbid conditions:

• hypertension

• Type 2 diabetes mellitus (T2DM)

• dyslipidemia

• obstructive sleep apnea, or

• cardiovascular disease.

• Have moderately to severely active CD defined by a CDAI score of at least 220 atbaseline.

• Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6for patients with ileal-colonic or ≥4 for patients with isolated ileal diseasewithin 21 days before the first dose of study treatment.

• Have a history of CD involving only or predominantly the colon for greater than orequal to 8 years with a surveillance colonoscopy within 1 year prior to baselinemust have documented negative results for colorectal dysplasia and cancer.

• Have an inadequate response to, loss of response to, or intolerance to:

• at least one conventional therapy (such as corticosteroids, oral azathioprine (AZA) or 60-mercaptopurine (6-MP), or oral aminosalicylates (for example,mesalamine, sulfasalazine, olsalazine, balsalazide) and/or,

• at least one advanced therapy for CD (defined as: a biologic or biosimilarmedication such as anti-tumor necrosis factor (TNF) antibodies, anti-integrinantibodies, Janus kinase (JAK) inhibitors such as upadacitinib, oranti-interleukin (IL)-12p40 antibodies, for example, ustekinumab).

Exclusion Criteria:

• Have a current diagnosis of Ulcerative Colitis (UC), inflammatory boweldisease-unclassified (formerly known as indeterminate colitis), or primarysclerosing cholangitis.

• Have more than 2 missing segments of the following 5 segments: terminal ileum, ·right colon, transverse colon, ·left colon, and rectum.

• Currently have or are suspected to have an abscess.

• Have a stoma, ileoanal pouch, or ostomy.

• Have a history of more than 3 small bowel resections, diagnosis of short bowelsyndrome, or any intestinal or non-intestinal intra-abdominal surgery within 3months of baseline.

• Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.

• Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6months prior to screening.

• Have had more than 5% body weight change in the past 3 months

• Have a current or recent acute, active infection.